| 41.5 0.39 (0.95%) | 10-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 49.07 | 1-year : | 57.32 |
| Resists | First : | 42.02 | Second : | 49.07 |
| Pivot price | 40.08  |
|||
| Supports | First : | 38.91 |
Second : | 37 |
| MAs | MA(5) : | 41.15 |
MA(20) : | 39.95 |
| MA(100) : | 35.79 |
MA(250) : | 32.46 |
|
| MACD | MACD : | 0.8 |
Signal : | 0.8 |
| %K %D | K(14,3) : | 75.8 |
D(3) : | 74.5  |
| RSI | RSI(14): 65.3 |
|||
| 52-week | High : | 42.02 | Low : | 18.82 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ TEVA ] has closed below upper band by 10.8%. Bollinger Bands are 7.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 41.75 - 41.91 | 41.91 - 42.03 |
| Low: | 40.54 - 40.74 | 40.74 - 40.9 |
| Close: | 41.21 - 41.51 | 41.51 - 41.75 |
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms of multiple sclerosis; AJOVY, prescribed for preventing migraines; and AUSTEDO, which targets tardive dyskinesia and chorea linked to Huntington's disease. For respiratory conditions, Teva offers medications such as ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick, all designed to treat asthma and chronic obstructive pulmonary disease. The oncology portfolio features therapies like Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited is also engaged in a collaboration with MedinCell to advance and commercialize multiple long-acting injectable formulations, notably a risperidone suspension for individuals affected by schizophrenia. The company was established in 1901 and its primary headquarters are located in Tel Aviv-Yafo, Israel.
Sat, 17 Oct 2026
Teva Pharmaceutical Industries Limited (TEVA) stock price, news, quote and history - Yahoo Finance UK
Fri, 16 Oct 2026
Inside Teva's Weltruza launch and Novo's GLP-1 strategy - Fierce Pharma
Fri, 16 Oct 2026
Mayne Settles US Patent Suit With Teva Over Generic Imvexxy - Law360
Wed, 14 Oct 2026
Cash per share of Teva Pharmaceutical Industries Limited – BIVA:TEVA1/N - TradingView
Mon, 12 Oct 2026
Teva Pharmaceutical Industries Ltd. to Host R&D Day on November 11, 2026 - Quiver Quantitative
Mon, 12 Oct 2026
Teva to Host R&D Day on Wednesday, November 11 in New York City - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 1,170 (M) |
| Shares Float | 1,090 (M) |
| Held by Insiders | 0.5 (%) |
| Held by Institutions | 24.4 (%) |
| Shares Short | 29,850 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.65 |
| Profit Margin | 4 % |
| Operating Margin | 4 % |
| Return on Assets (ttm) | 5.1 % |
| Return on Equity (ttm) | 9.6 % |
| Qtrly Rev. Growth | -0.9 % |
| Gross Profit (p.s.) | 7.76 |
| Sales Per Share | 14.8 |
| EBITDA (p.s.) | 3.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1,900 (M) |
| Levered Free Cash Flow | 2,220 (M) |
| PE Ratio | 69.16 |
| PEG Ratio | 0.7 |
| Price to Book value | 6.24 |
| Price to Sales | 2.8 |
| Price to Cash Flow | 25.55 |
| Dividend | 0.09 |
| Forward Dividend | 0 |
| Dividend Yield | 0.2% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|